BIOX Valuation

Bioceres Crop Solutions Corp

Add to Watchlist

Advanced Chart

1.660

-0.1(-5.682%)1D

BIOX Relative Valuation

BIOX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIOX is overvalued; if below, it's undervalued.

Historical Valuation

Bioceres Crop Solutions Corp (BIOX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.76 is considered Fairly compared with the five-year average of 23.89. The fair price of Bioceres Crop Solutions Corp (BIOX) is between 1.65 to 2.48 according to relative valuation methord.

Relative Value

Fair Zone

1.65-2.48

Current Price：1.76

Fair

-7.23

Trailing

Forward

7.51

EV/EBITDA

Bioceres Crop Solutions Corp. (BIOX) has a current EV/EBITDA of 7.51. The 5-year average EV/EBITDA is 10.10. The thresholds are as follows: Strongly Undervalued below 5.94, Undervalued between 5.94 and 8.02, Fairly Valued between 12.18 and 8.02, Overvalued between 12.18 and 14.26, and Strongly Overvalued above 14.26. The current Forward EV/EBITDA of 7.51 falls within the Undervalued range.

16.28

EV/EBIT

Bioceres Crop Solutions Corp. (BIOX) has a current EV/EBIT of 16.28. The 5-year average EV/EBIT is 14.00. The thresholds are as follows: Strongly Undervalued below 7.10, Undervalued between 7.10 and 10.55, Fairly Valued between 17.45 and 10.55, Overvalued between 17.45 and 20.89, and Strongly Overvalued above 20.89. The current Forward EV/EBIT of 16.28 falls within the Historic Trend Line -Fairly Valued range.

1.76

Bioceres Crop Solutions Corp. (BIOX) has a current PS of 1.76. The 5-year average PS is 1.48. The thresholds are as follows: Strongly Undervalued below 0.44, Undervalued between 0.44 and 0.96, Fairly Valued between 2.00 and 0.96, Overvalued between 2.00 and 2.52, and Strongly Overvalued above 2.52. The current Forward PS of 1.76 falls within the Historic Trend Line -Fairly Valued range.

2.60

P/OCF

Bioceres Crop Solutions Corp. (BIOX) has a current P/OCF of 2.60. The 5-year average P/OCF is 15.18. The thresholds are as follows: Strongly Undervalued below -56.64, Undervalued between -56.64 and -20.73, Fairly Valued between 51.10 and -20.73, Overvalued between 51.10 and 87.01, and Strongly Overvalued above 87.01. The current Forward P/OCF of 2.60 falls within the Historic Trend Line -Fairly Valued range.

3.16

P/FCF

Bioceres Crop Solutions Corp. (BIOX) has a current P/FCF of 3.16. The 5-year average P/FCF is 45.90. The thresholds are as follows: Strongly Undervalued below -169.57, Undervalued between -169.57 and -61.83, Fairly Valued between 153.64 and -61.83, Overvalued between 153.64 and 261.37, and Strongly Overvalued above 261.37. The current Forward P/FCF of 3.16 falls within the Historic Trend Line -Fairly Valued range.

Bioceres Crop Solutions Corp (BIOX) has a current Price-to-Book (P/B) ratio of 0.36. Compared to its 3-year average P/B ratio of 1.94 , the current P/B ratio is approximately -81.54% higher. Relative to its 5-year average P/B ratio of 3.39, the current P/B ratio is about -89.45% higher. Bioceres Crop Solutions Corp (BIOX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.50%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.48% , the current FCF yield is about -100.00% lower.

0.36

P/B

Median3y

1.94

Median5y

3.39

0.00

FCF Yield

Median3y

2.50

Median5y

0.48

Competitors Valuation Multiple

The average P/S ratio for BIOX's competitors is 3.82, providing a benchmark for relative valuation. Bioceres Crop Solutions Corp Corp (BIOX) exhibits a P/S ratio of 1.76, which is -53.92% above the industry average. Given its robust revenue growth of -40.15%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BIOX.O

Bioceres Crop Solutions Corp

American Vanguard Corp

Snow Lake Resources Ltd

Arcadia Biosciences Inc

Performance Decomposition

Market capitalization of BIOX decreased by 75.28% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.67 to -64.52.

The secondary factor is the Revenue Growth, contributed -40.15%to the performance.

Overall, the performance of BIOX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-40.15%

124.31M → 74.40M

Revenue Growth

3763.47%

-1.67 → -64.52

Margin Expansion

-3798.60%

0.06 → -2.15

P/E Change

-75.28%